Computer-Aided Drug Design: Current Approaches, Challenges, and Future Perspectives

Computer-aided drug design (CADD) is an important computational approach in modern drug discovery and development. Conventional drug discovery is time-consuming, costly, and complex, with a high risk of failure. CADD supports the identification, design, evaluation, and optimization of potential drug candidates through computational tools and molecular modelling techniques. This review outlines the principal methods, applications, advantages, limitations, and recent advances in CADD. It discusses the two major approaches—structure-based drug design (SBDD) and ligand-based drug design (LBDD)—along with molecular docking, virtual screening, quantitative structure–activity relationship (QSAR) analysis, pharmacophore modelling, molecular dynamics simulation, de novo drug design, and ADMET prediction. These methods can support target identification, hit discovery, lead optimization, drug repurposing, and the early assessment of pharmacokinetic and toxicity-related properties. The review also considers the growing role of artificial intelligence (AI) and machine learning (ML) in predicting molecular properties, prioritizing candidate compounds, and informing drug-design strategies. Despite their potential, CADD methods face challenges involving data quality, prediction accuracy, computational demands, and model validation. Experimental studies therefore remain essential to confirm the biological activity, safety, and therapeutic potential of computationally predicted compounds. Overall, integrating CADD with experimental research may improve the efficiency of drug discovery and pharmaceutical development.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24414541
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Computer-Aided Drug Design: Current Approaches, Challenges, and Future Perspectives

Samiksha Patil, Tejas Kakad, Suraj Rajurkar, Aditya Rudarkar et al.
Zenodo (CERN European Organization for Nuclear Research)
Computational Drug Discovery Methods
article

Computer-Aided Drug Design: Current Approaches, Challenges, and Future Perspectives

Samiksha Patil, Tejas Kakad, Suraj Rajurkar, Aditya Rudarkar, Palak Shende, Bhushan Pote
article en

Abstract

Computer-aided drug design (CADD) is an important computational approach in modern drug discovery and development. Conventional drug discovery is time-consuming, costly, and complex, with a high risk of failure. CADD supports the identification, design, evaluation, and optimization of potential drug candidates through computational tools and molecular modelling techniques. This review outlines the principal methods, applications, advantages, limitations, and recent advances in CADD. It discusses the two major approaches—structure-based drug design (SBDD) and ligand-based drug design (LBDD)—along with molecular docking, virtual screening, quantitative structure–activity relationship (QSAR) analysis, pharmacophore modelling, molecular dynamics simulation, de novo drug design, and ADMET prediction. These methods can support target identification, hit discovery, lead optimization, drug repurposing, and the early assessment of pharmacokinetic and toxicity-related properties. The review also considers the growing role of artificial intelligence (AI) and machine learning (ML) in predicting molecular properties, prioritizing candidate compounds, and informing drug-design strategies. Despite their potential, CADD methods face challenges involving data quality, prediction accuracy, computational demands, and model validation. Experimental studies therefore remain essential to confirm the biological activity, safety, and therapeutic potential of computationally predicted compounds. Overall, integrating CADD with experimental research may improve the efficiency of drug discovery and pharmaceutical development.

Zenodo (CERN European Organization for Nuclear Research)
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Computer-Aided Drug Design: Current Approaches, Challenges, and Future Perspectives — Samiksha Patil, Tejas Kakad, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS